Enexis AB has invested in Valcon Medical, a Danish contract manufacturer specializing in medical cannabis extracts, capitalizing on the growing demand in the evolving cannabis market.
Information on the Target
Valcon Medical is a Danish contract manufacturing organization that specializes in the production of medical cannabis extracts. The company has established itself as a key player in the medical cannabis sector, focusing on high-quality manufacturing processes and compliance with stringent regulatory requirements. Valcon Medical is well-positioned to meet the growing demand for medical cannabis products, leveraging advanced technologies and industry expertise.
With a commitment to innovation and quality assurance, Valcon Medical aims to provide its clients with reliable and effective cannabis-based solutions. The company has built a robust reputation in the market, catering to various stakeholders, including pharmaceutical companies and healthcare providers.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Denmark
The medical cannabis industry in Denmark has experienced significant growth in recent years, reflecting a broader trend across Europe. Following the Danish government's regulatory framework established in 2018, the market has opene
Similar Deals
Syndicate of five investors from Keystones and DanBAN → OfficeFit
2025
Lundbeck Foundation BioCapital, EIR Ventures, EIFO, UCPH Ventures → Dania Therapeutics
Enexis
invested in
Valcon Medical
in 2022
in a Other VC deal